ENStem cell treatment for the eyes in Germany is possible in one case, limbal damage at the edge of the cornea, but in most other conditions not yet. This page is for readers who have heard that stem cells already cure blindness and want to know whether that is true and possible in Germany.
It separates three things: recognised treatment, treatment within a clinical trial and commercial offers without evidence. For the whole field, see eye hospitals in Germany.
What stem cell treatment means in ophthalmology
In ophthalmology, it means trying to restore eye tissue with stem cells, which can divide and turn into the cells of a particular tissue. The eye has several stem cell reserves; the best studied is the limbus, a narrow ring where the clear cornea meets the white of the eye.
The key distinction: restoring the surface of the eye, where stem cells really exist and can multiply, is one thing; restoring dead light-sensitive retinal cells or optic nerve fibres is quite another. The first is done, the second is being studied; for other uses, see stem cell therapy: what is proven.
Where it already works: limbal damage and the cornea
It works in limbal stem cell deficiency: after a chemical or thermal burn, severe inflammation or a rare congenital condition, the stem cell reserve at the edge of the cornea runs out, and the cornea clouds over and grows blood vessels. A standard corneal transplant does not help, because the new cornea has nothing to maintain its surface.
Treatment means transplanting a piece of limbus from the patient’s healthy eye or a donor. Alternatively, the patient’s own cells from a small piece of healthy limbus are grown in a laboratory and transplanted: Holoclar, an advanced therapy medicinal product made this way, is authorised in the EU for adults with the deficiency after a burn. The aim is to restore a clear surface; a corneal transplant may then be discussed.
Three things set this apart from «stem cell injections»: it is tied to a specific diagnosis, done in an eye hospital with a corneal surgery department and requires long follow-up. The methods and their limits are described in a peer-reviewed review on limbal stem cell deficiency.
Where it is still research: the retina and the optic nerve
In retinal and optic nerve disease, cell therapy is a matter of clinical trials, not a service on a price list. Work is under way in age-related macular degeneration, retinitis pigmentosa (an inherited retinal disease), optic nerve atrophy and glaucoma, but no results today would allow anyone to promise sight back. For current options, see optic nerve atrophy treatment and macular degeneration treatment.
In practice, taking part is possible, but only within the selection criteria: diagnosis, stage, age, the state of the other eye. A place cannot be bought: under Article 92 of Regulation (EU) No 536/2014, participants do not bear the costs of investigational products or protocol procedures unless national law provides otherwise. Being asked to pay is the sign that this is not a trial.
A quick answer cannot be expected: a dead nerve cell is not replaced by placing another beside it. The new cell must join the network of connections in the retina and, in optic nerve disease, grow a fibre to the brain; that is exactly what remains unsolved.
How to tell a trial from a paid promise
A few questions asked before any payment tell the two apart.
- Is there a trial registration number and a protocol? Check it in a public register: the German DRKS, the European CTIS or ClinicalTrials.gov.
- Who funds the trial?
- Is the patient charged for the treatment itself?
- Are the risks named in the written consent?
- Is a result promised? In a trial it cannot be.
- Does the same «stem cell therapy» treat a dozen different diseases at once? That reliably signals a commercial offer.
The legal frame: in Germany, cell preparations count as medicinal products subject to authorisation rules, with the Paul-Ehrlich-Institut as the competent federal authority for advanced therapy medicinal products. So treatment outside a trial and outside an authorised product is not a lawful service; see is stem cell therapy allowed in Germany.
Where this is done in Germany
The field belongs to university eye hospitals with corneal surgery. Among AlenMed’s partners is the University Eye Hospital Heidelberg, which has a department for corneal and transplant surgery and is headed by Prof. Gerd U. Auffarth.
In retinal disease, a trip most often offers not cell therapy but an exact diagnosis, genetic testing in inherited forms and a clear follow-up plan.
Frequently asked questions
Can stem cells restore sight?
So far only in one case: recognised treatment exists for limbal stem cell deficiency and can restore a clear surface of the eye, after which a corneal transplant may be discussed. For the retina and the optic nerve, cell therapy is still research, with no results that would allow anyone to promise sight back.
Who is a candidate for a limbal stem cell transplant?
People whose limbal stem cell reserve has run out after a chemical or thermal burn, severe inflammation or a rare congenital condition. Tissue comes from the healthy other eye or a donor; the product grown from the patient’s own cells is authorised in the EU for adults after a burn. A corneal surgeon decides after an examination.
How can I join a trial of cell therapy for the eyes?
Through a doctor at an eye hospital, who can say whether a suitable trial is running and whether you meet its criteria: diagnosis, stage, age, the state of the other eye. Participants do not pay for the investigational product; a request for payment means it is not a trial.
How AlenMed arranges the consultation
AlenMed sends your documents to an eye hospital before any trip: reports, OCT scans and visual fields as files, the cause of the sight loss, discharge letters after a burn or surgery. The doctor answers whether a recognised treatment exists for this diagnosis, whether a suitable trial is running and whether a trip makes sense; then come a written estimate, a visa invitation, appointments and an interpreter.
We say this in advance: the answer «there is no recognised cell treatment for your diagnosis» is also a consultation result, and it saves money in places that promise the opposite.
This material is for information only and is not an offer; the indication and the possibility of treatment are decided by a doctor in person.
News on this topic
New Retinal Chip PRIMA Restores Central Vision in Geographic Atrophy
A newly approved photovoltaic subretinal chip offers restored visual function for patients with central vision loss from geographic atrophy due to dry AMD.
